Navigation Links
Generex Announces Results of Annual Stockholders' Meeting
Date:6/10/2011

, and more than 295 million shares outstanding, the voter turnout here is nothing short of remarkable."  Mr. Fletcher continued, "I note that more than 80% of the shares voted were in favour of the reverse stock split.  This vote is an endorsement of the new Generex management team and Board of Directors, and provides a clear mandate to proceed with the development plan unveiled by the Company on March 30, 2011."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
2. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
3. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
4. Generex Announces $3.0 Million Capital Investment
5. Generex Provides Additional Details for October 21st Live Video Webcast
6. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
7. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
8. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
9. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
10. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
11. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics established ... annual meeting drew praise from community leaders from SPIE ... the action “a huge step forward … a lasting ... , The Board of Stakeholders voted to approve in ... its 29 April meeting in Brussels, which was sponsored ...
(Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
(Date:5/17/2013)... , May 17, 2013  Yongye International, Inc. ... a leading developer, manufacturer, and distributor of crop nutrient ... , today announced that, on May 16, 2013, ... of directors (the "Board of Directors") was provided a ... Hong Kong ) Limited ("Abax") to Full ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... July 27, 2011 Once routinely discarded during the ... and potentially life-saving stem cells that can be collected ... proven uses and vast medical potential, published data shows ... "minimally informed" about cord blood banking. In ...
... July 27, 2011 Peloton Therapeutics, Inc., an early-stage ... completion of an $18 million Series A financing.  Led ... and Peter O,Donnell, Jr., the Series A funds supplement ... Prevention and Research Institute of Texas (CPRIT). ...
... LLC, a Chicago-based healthcare private equity firm, today ... Strata Pathology Services, Inc., a leading independent anatomic ... in Lexington, Massachusetts, Strata offers anatomic pathology services ... and gynecology segments. Since 1984, the company has ...
Cached Biology Technology:Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 2Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 3Peloton Therapeutics Completes $18 Million Series A Financing 2Peloton Therapeutics Completes $18 Million Series A Financing 3Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... CAMBRIDGE, MA -- Injectable nanoparticles developed at MIT ... Type 1 diabetes to constantly monitor their blood-sugar ... nanoparticles were designed to sense glucose levels in ... amount of insulin, thereby replacing the function of ... with Type 1 diabetes. Ultimately, this type of ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... influenza (H1N1) outbreak is the subject of a landmark ... Sciences on Thursday, May 28. Speakers will discuss the ... public health implications of a worldwide pandemic. ... 12:30 p.m. to 5:30 p.m., at academy offices, 7 ...
... The Society of Environmental Toxicology and Chemistry will host ... theme of "Protecting Ecosystem Health: Facing the Challenge of ... at the Gothenburg Convention Centre, Sweden. Nanotechnology,s ... of contaminants at the molecular level, polar ecotoxicology, and ...
... written by Rosa Binimelis, Walter Pengue and Iliana Monterroso, ... University of Barcelona, University of Buenos Aires and the ... The article describes the geographical advance of the invasion ... the invasion process to discuss the major drivers and ...
Cached Biology News:SETAC Europe addresses global ecosystem health in Gothenburg 2Weed resistance to glyphosate in genetically modified soybean cultivation in Argentina 2
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
... The CultureWell cell culture systems ... preparing cultured cells for staining ... medical-grade silicone gaskets preassembled with ... culture plates. The entire system ...
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
Protein Phosphorylation...
Biology Products: